Healthcare

Yseop’s first CMC-focused offering automates the Quality Overall Summary (Module 2.3), a central component of regulatory submissions that pulls structured insights from Module 3.2.

The FDA has begun using generative AI to review drug submissions, signaling a major shift in regulatory review. Learn how this impacts pharma teams and what it takes to make your content AI-ready.

The AI landscape is evolving rapidly. While pre-configured workflows have powered automation for years, the next frontier lies in intelligent AI agents—systems that can plan, adapt and execute tasks dynamically rather than following static scripts.